Free Trial
NASDAQ:GTBP

GT Biopharma (GTBP) Stock Price, News & Analysis

GT Biopharma logo
$2.33 -0.12 (-4.90%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$2.42 +0.09 (+4.03%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GT Biopharma Stock (NASDAQ:GTBP)

Key Stats

Today's Range
$2.33
$2.52
50-Day Range
$2.15
$2.56
52-Week Range
$1.72
$10.66
Volume
9,378 shs
Average Volume
580,329 shs
Market Capitalization
$5.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Strong Buy

Company Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GT Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

GTBP MarketRank™: 

GT Biopharma scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GT Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GT Biopharma has received no research coverage in the past 90 days.

  • Read more about GT Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for GT Biopharma are expected to grow in the coming year, from ($6.79) to ($2.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GT Biopharma is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GT Biopharma is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GT Biopharma has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about GT Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.27% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GT Biopharma has recently decreased by 30.01%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    GT Biopharma does not currently pay a dividend.

  • Dividend Growth

    GT Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.27% of the float of GT Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    GT Biopharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GT Biopharma has recently decreased by 30.01%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, GT Biopharma insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      10.90% of the stock of GT Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 8.15% of the stock of GT Biopharma is held by institutions.

    • Read more about GT Biopharma's insider trading history.
    Receive GTBP Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

    GTBP Stock News Headlines

    URGENT: Someone's Moving Gold Out of London...
    People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
    GT Biopharma Announces Exercise of Warrants
    See More Headlines

    GTBP Stock Analysis - Frequently Asked Questions

    GT Biopharma's stock was trading at $3.05 at the beginning of 2025. Since then, GTBP shares have decreased by 23.6% and is now trading at $2.33.
    View the best growth stocks for 2025 here
    .

    GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings data on Thursday, April, 15th. The company reported ($101.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $100.50.

    GT Biopharma shares reverse split before market open on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

    Top institutional shareholders of GT Biopharma include DekaBank Deutsche Girozentrale. Insiders that own company stock include Michael Martin Breen and Manu Ohri.
    View institutional ownership trends
    .

    Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that GT Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Meta Platforms (META), CrowdStrike (CRWD) and Intel (INTC).

    Company Calendar

    Last Earnings
    4/15/2021
    Today
    5/04/2025
    Next Earnings (Estimated)
    5/13/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:GTBP
    Previous Symbol
    OTCMKTS:OXISD
    Fax
    N/A
    Employees
    8
    Year Founded
    1965

    Price Target and Rating

    Average Stock Price Target
    $11.00
    High Stock Price Target
    $11.00
    Low Stock Price Target
    $11.00
    Potential Upside/Downside
    +372.1%
    Consensus Rating
    Strong Buy
    Rating Score (0-4)
    3.50
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-7,600,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $5.42 per share
    Price / Book
    0.43

    Miscellaneous

    Free Float
    1,990,000
    Market Cap
    $5.91 million
    Optionable
    No Data
    Beta
    1.48

    Social Links

    10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

    Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

    Get This Free Report

    This page (NASDAQ:GTBP) was last updated on 5/5/2025 by MarketBeat.com Staff
    From Our Partners